WhiteSwell Develops a Different Way to Treat Heart Failure

A small medtech company is looking at tackling a huge problem in one of the toughest markets to navigate in healthcare. Galway, Ireland-based WhiteSwell has set its sights on developing a minimally invasive catheter approach that can drain the excess fluid that can be found in acute decompensated heart failure (ADHF) patients. But WhiteSwell isn’t going into this endeavor unprepared or without support. The small medtech company said it has just raised $30 million in a round led by RA Capital Management and an InCube Ventures syndicate, with participation from other investors. “The $30 million is a pretty sizable raise for a company that is just 4-years-old,” Eamon Brady, WhiteSwell’s CEO, told MD+DI. “The funding will be used to advance product development in a second generation of our technology that is in the pipeline at the moment. We want to bring that to the clinic.” Funds from the round will also be used to support a pivotal study of WhiteSwell’s technology. “We’re looking forward to working with WhiteSwell’s experienced leadership team to deliver a compelling new therapy for ADHF, and we see the potential for it to become a blockbuster medtech product,” Andrew Farquharson, Managing Director and Co-founder of InCube Ventures, said in a release. “The WhiteSwe...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news